在多金属微粒中延长释放原生药物
Shutao Guo1, Yoshiyuki Nakagawa1, Aoune Barhoumi1
1Laboratory for Biomaterials and Drug Delivery, Division of Critical Care Medicine, Children's Hospital Boston, Harvard Medical School , 300 Longwood Avenue, Boston, Massachusetts 02115, United States.
Journal of the American Chemical Society
|May 6, 2016
概括
研究人员开发了高分子量多基甲药物合物,用于长效的药物. 这些可生物降解,生物相容的微粒提供长时间的,对酸反应的药物释放,
科学领域:
- 生物医学工程
- 聚合物化学
- 药物输送系统
背景情况:
- 在生物医学应用中提供生物降解性,生物相容性和pH敏感性.
- 在合成高分子量聚乙烯和从颗粒配方中实现持续的药物释放方面存在挑战.
研究的目的:
- 使用新型单体合成高分子量多金属药物联体.
- 开发用于长时间和响应性药物释放的微粒配方.
主要方法:
- 合成了一种二异乙醇单体,用于加聚化.
- 创建了具有高药载荷的雌激醇多基甲结合微粒.
- 在不同的pH条件下和PLGA的联合结合下,研究了雌激素释放动力学.
主要成果:
- 实现了高分子量聚乙烯-雌二醇合物的合成.
- 微粒显示高药载荷和显著延长的雌激素释放.
- 雌激素的释放对酸有反应,在较低的pH值下加速.
- 在体内研究显示对微粒的良性组织反应.
结论:
- 聚甲基药物合物是长效药物输送的可行策略.
- 开发的微粒适用于治疗需要持续治疗水平的慢性疾病.
- 提供可调节的药物输送概况.
相关概念视频
Site-Targeted Drug Delivery Systems: Polymeric Carriers
103
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
103
Modified-Release Drug Delivery Systems: Rate-Programmed II
74
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
74
Oral Drug Delivery Systems: Delayed-Release Systems
125
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
125
Modified-Release Drug Delivery Systems: Drug Release Characteristics
157
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
157
Modified-Release Drug Delivery Systems: Classification
229
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
229
Modified-Release Drug Delivery Systems: Site-Targeted
91
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
91


